Overactive Bladder & Urinary Incontinence Treatments
|OVERACTIVE BLADDER &
URINARY INCONTINENCE TREATMENTS
|imipramine HCl||Tofranil||tabs||10mg, 25mg, 50mg||<6yrs: Not established.
≥6yrs: Initially 25mg daily 1hr before bedtime; after 1wk, increase to 50mg for children 6−12yrs, up to 75mg for those >12yrs.
Early night bedwetters: Give 25mg in afternoon and repeat at bedtime.
Max 2.5mg/kg per day.
|darifenacin HBr||Enablex||ext-rel tabs||7.5mg, 15mg||Children: Not recommended.
Adults: Initially 7.5mg once daily; may increase to 15mg once daily after 2wks. Max 7.5mg once daily in moderate hepatic impairment or with potent CYP3A4 inhibitors (eg, ketoconazole, itraconazole, ritonavir, nelfinavir, clarithromycin, nefazadone).
|oxybutynin chloride||—||scored tabs||5 mg||<5yrs: Not recommended.
≥5yrs: 5mg twice daily; max 15mg/day
Adults: 5mg 2−3 times a day; max 20mg/day
|ext-rel tabs||5mg, 10mg, 15mg||<6yrs: Not recommended.
≥6yrs: Initially 5mg once daily; may increase in 5mg increments; max 20mg/day.
Adults: Initially 5mg or 10mg once daily; may increase weekly in 5mg increments; max 30mg/day.
|Children: Not established.
Adults: Apply one sachet once daily to dry, intact skin. Rotate application sites.
|oxybutynin transdermal system||Oxytrol||patch||3.9mg/
|Children: Not established.
Adults: Apply 1 patch twice weekly (every 3−4 days) to clean, dry area on the abdomen, hip or buttock. Rotate application sites.
|solifenacin succinate||Vesicare||tabs||5mg, 10mg||Children: Not established.
Adults: Initially 5mg once daily; if well tolerated, may increase to 10mg once daily. Severe renal impairment (CrCl<30mL/min), moderate hepatic impairment, or concomitant potent CYP3A4 inhibitors (eg, ketoconazole): max 5mg once daily.
|trospium chloride||Sanctura||tabs||20mg||Children: Not established.
Adults: 20mg twice daily. ≥75yrs: 20mg once daily if twice daily dose not tolerated. Severe renal impairment (CrCl<30mL/min): 20mg once daily at bedtime.
|Sanctura XR||ext-rel caps||60mg||Children: Not established.
Adults: 60mg daily in the AM. Severe renal impairment (CrCl<30mL/min): not recommended.
|fesoterodine fumarate||Toviaz||ext-rel tabs||4mg, 8mg||Children: Not recommended.
Adults: 4mg once daily; max 8mg once daily. Severe renal insufficiency (CrCl<30mL/min) or concomitant potent CYP3A4 inhibitors (eg, ketoconazole, itraconazole, clarithromycin): max 4mg/day.
|tolterodine tartrate||Detrol||tabs||1mg, 2mg||Children: Not established.
Adults: 2mg twice daily; may decrease to 1mg twice daily. Concomitant CYP3A4 inhibitors, or significant renal or hepatic dysfunction: 1mg twice daily.
|Detrol LA||ext-rel caps||2mg, 4mg||Children: Not established.
Adults: 4mg once daily; may decrease to 2mg once daily. Concomitant CYP3A4 inhibitors, or significant renal or hepatic dysfunction: 2mg once daily.
|Botox||vacuum-dried pwd; for intra-
detrusor inj after reconsti-
tution and dilution
|50 U/vial, 100 U/vial, 200 U/vial||<18yrs: Not established.
Adults: See full labeling. Should be administered and managed by experienced physicians. Give prophylactic antibiotics 1−3 days pre‑treatment, during, and 1−3 days post‑treatment. Discontinue anti-platelet therapy ≥3 days before procedure. May premedicate with local or general anesthetic. Max dose: 100 Units/treatment; give 20 injections of 0.5mL each into the detrusor muscle via a flexible or rigid cystoscope, avoiding the trigone. May consider re‑treatment after effect of the previous injection diminishes but no sooner than 12wks. Max cumulative dose: 400 Units in a 3‑month interval.
|DDAVP||scored tabs||0.1mg, 0.2mg||<6yrs: Not recommended.
≥6yrs: Initially 0.2mg once daily at bedtime; individualize; max 0.6mg.
Not an inclusive list of medications and/or official indications. Please see drug monograph at www.eMPR.com and/or contact company for full drug labeling.